ABSTRACT
INTRODUCTION
For many years, surgery has been accepted as the standard therapy for relieving bladder outlet obstruction secondary to benign prostate hyperplasia (BPH). In recent years, the introduction of medical therapy has dramatically changed the landscape of BPH management, and surgery mainly in the form of transurethral resection of the prostate, laser procedures, or open adenomectomy has been pushed to the second line and offered to patients mainly when they fail medial therapy.
Consequently, the total rate of all BPH procedures has progressively declined [1] . Transurethral microwave therapy and transurethral needle ablation of the prostate are characterized by higher retreatment rates with respect to conventional surgery [2] .
a1-Blockers (ABs) represent the mainstay of medical therapy for BPH. They are recommended in men with moderate-to-severe lower urinary tract symptoms related to benign prostatic enlargement (LUTS/BPE).
5-Alpha-reductase inhibitors can be offered in men who have moderate-to-severe LUTS and an enlarged prostate ([40 mL) [2] . They can prevent disease progression with regard to acute urinary retention and need for surgery [2] . ABs are often considered the first-line drug treatment of male LUTS because of their rapid onset of action, good efficacy, and low rate and severity of adverse events [2] . They can be prescribed in combination with 5-alpha-reductase inhibitors in men with troublesome moderate-to severe LUTS, enlarged prostate, and reduced peak urinary flow (Qmax) [2] . To date, six ABs have been approved for the treatment of LUTS/BPE:
terazosin, doxazosin, tamsulosin, naftopidil, alfuzosin, and silodosin [2] . Naftopidil has been approved for the treatment of LUTS/BPE only in Japan, China, and South Korea. ABs inhibit a 1 -adrenergic receptors (a 1 -AR) and aim to counteract the effects of endogenously released catecholamines at the level of the lower urinary tract in order to reduce bladder outlet resistance [2] . All available ABs have been reported to significantly improve LUTS with respect to placebo [2] . Although there are no specific indications in favor of one drug over others under specific clinical situations, ABs have different profiles of uroselectivity, a feature that can be defined on the basis of pharmacologic, functional, or clinical features [3, 4] . Silodosin is the most recent AB approved by the US Food and Drug Administration for the treatment of LUTS/BPE (October 2008). The aim of the present review is to summarize the available evidence about pharmacodynamic, urodynamic, and clinical features of silodosin with respect to other ABs.
Compliance with Ethics Guidelines
This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors. Tamsulosin is 15-and 3-fold more selective for the a 1A -AR subtype than for the a 1B -AR and a 1D -AR subtypes [10, 11] . Naftopidil is a subtype-selective AB with high affinity for the a 1D -AR. It has a three times greater affinity for the a 1D -AR subtype than for the a 1A -AR subtype. Silodosin is highly selective for a 1A -AR, with a 162-fold greater affinity than for a 1B -AR and about a 50-fold greater affinity than for a 1D -AR [8, 11] .
PHARMACOLOGICAL AND FUNCTIONAL SELECTIVITY PROFILE
Functional uroselectivity has been defined using in vitro and in vivo methodologies. The in vitro methodology involves the comparison of the relative affinity of the ABs to inhibit prostate or vascular smooth muscle, whereas in vivo methodologies are based on relative potency for reducing intraurethral pressure versus lowering blood pressures [3] . Tatemichi et al. investigated the selectivity of silodosin for the three distinct a 1 -AR subtypes by means of receptor-binding and functional pharmacological studies and compared its subtype-selectivity with those of other ABs [12] . Silodosin showed higher selectivity for the a 1A -AR subtype than tamsulosin or prazosin [12] . Moreover, silodosin strongly antagonized noradrenaline-induced contractions in rabbit lower urinary tract tissues (including prostate, urethra, and bladder trigone) with respect to noradrenaline-induced contractions in rat isolated spleen and rat isolated thoracic aorta [12] . Silodosin was about 280 times more selective for prostate tissue than for splenic tissue and about 50 times more selective than for thoracic aortic tissue [12] . Furthermore, the selectivity for the urethra and bladder trigone was found to be comparable with that for the prostate [12] . The selectivity of tamsulosin for the prostate was about 20 times higher than that of selectivity for spleen, but comparable with that for the thoracic aorta [12] . Prazosin was more selective for the spleen and thoracic aorta showing the selectivity for the prostate to be lower [12] . To evaluate in vivo uroselectivity (ratio of reactivities for lower urinary tract against blood pressure) several animal studies have been performed. Tatemichi 
CLINICAL EFFICACY AND SAFETY
Clinical uroselectivity is defined in the clinical setting by comparing outcomes to side effects [3] . According to some authors, the only relevant selectivity in the treatment of LUTS/ BPE is clinical selectivity [3] . The relevance of a 1 -AR subtype pharmacologic selectivity on the clinical usefulness of existing drug therapies has not been firmly established. However, it has been suggested that selective blockade of a 1 -AR subtypes is necessary for the optimum balance between clinical efficacy and adverse effects [4] .
In fact, most serious adverse events with ABs are cardiovascular and mediated by a 1B -AR antagonism.
URODYNAMIC EFFICACY
Historically, it has been assumed that ABs are able to improve LUTS/BPE by reducing benign prostatic obstruction (BPO) thanks to the relaxing effect on prostatic smooth muscle. of an open, nonrandomized, nonblinded, single-center, prospective study [13] . The authors found statistically significant improvements of both free uroflowmetry and PFS variables. PdetQmax significantly decreased from 72.5 to 51.4 cmH 2 O and Qmax at PFS significantly increased from 5.9 to 8.8 mL/s (p = 0.0001) [13] . BOOI decreased in all patients and mean BOOI significantly decreased from 60.6 to 30.8 (p\0.0001) [13] .
According to the Schaefer nomogram, the degree of obstruction improved by three levels in 8 patients, by two levels in 20 patients, by one level in 28 patients, and was unchanged in 1 patient [13] . A further study was published in 2010 by Yamanishi et al. [14] . Thirty-six male patients with LUTS/BPE who were candidates for surgery were included into the study protocol [14] . Patients were asked to take silodosin 4 mg twice daily for 3 months [14] .
Baseline and post-treatment urodynamic data were available from 29 patients. The authors found a statistically significant decrease of both (Fig. 1) . Considering that 20 points in terms of BOOI are necessary to shift from obstructed to equivocal or from equivocal to unobstructed classes, we could define as clinically relevant the BOOI improvement under therapy with silodosin. These data support a hypothetical link between urodynamic efficacy and pharmacological selectivity. However, the further studies are needed to further elucidate this hypothesis.
However, the cited meta-analysis has some limitations: the few available studies are often outdated, the number of patients is small, only three randomized controlled trials of good methodological quality were available.
Moreover, studies were different in terms of populations enrolled and duration of treatment.
Finally, a potential limit of evidence on silodosin is that data derived from Japanese patients may not be representative of Caucasians. frequency-volume chart in a prospective multicenter study [6] . Interestingly, the authors found a significant reduction of nocturnal urine volume at 12 weeks compared to screening (p = 0.001) [6] . We can hypothesize that reduction of nocturnal polyuria combined with improved functional bladder capacity are potential mechanisms of action of ABs on nocturia and that this effect it is related to Silodosin exhibits cardiovascular safety in efficacy trials with events rate similar to placebo. In a pooled analysis of the US and European trials, the incidence of orthostatic hypotension was 1.3% in silodosin recipients and 1.1% in placebo recipients [11] . EjD does not represent a safety concern because it indicates only a reduction in semen volume that is reversible within a few days upon discontinuation of treatment and is not generally perceived as particularly bothersome [16] . The risk of EjD due to ABs therapy is much lower than that from surgical intervention for BPH and it is rarely serious enough to prompt patients to withdraw from treatment [36] .
Moreover, it has been suggested that patients with EjD are those with larger improvements in LUTS and Qmax as compared with those without EjD and this data may explain the very low discontinuation rate [11] . 
